Information Journal Paper
APA:
Copy. (2018). 273PD_PRFinal analysis of the Male-GBG54 study: A prospective, randomised multi-centre phase II study evaluating endocrine treatment with either tamoxifen +/-gonadotropin releasing hormone analogue (GnRHa) or an aromatase inhibitor + GnRHa in male breast cancer patients. Annals of Oncology, 29(suppl. 8), 0-0. SID. https://sid.ir/paper/780651/en
Vancouver:
Copy. 273PD_PRFinal analysis of the Male-GBG54 study: A prospective, randomised multi-centre phase II study evaluating endocrine treatment with either tamoxifen +/-gonadotropin releasing hormone analogue (GnRHa) or an aromatase inhibitor + GnRHa in male breast cancer patients. Annals of Oncology[Internet]. 2018;29(suppl. 8):0-0. Available from: https://sid.ir/paper/780651/en
IEEE:
Copy, “273PD_PRFinal analysis of the Male-GBG54 study: A prospective, randomised multi-centre phase II study evaluating endocrine treatment with either tamoxifen +/-gonadotropin releasing hormone analogue (GnRHa) or an aromatase inhibitor + GnRHa in male breast cancer patients,” Annals of Oncology, vol. 29, no. suppl. 8, pp. 0–0, 2018, [Online]. Available: https://sid.ir/paper/780651/en